{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,12]],"date-time":"2023-11-12T00:35:46Z","timestamp":1699749346561},"reference-count":15,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T00:00:00Z","timestamp":1205712000000},"content-version":"vor","delay-in-days":9694,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[1981,9]]},"abstract":"<jats:title>SUMMARY<\/jats:title><jats:p>Seventeen undialysed adult patients with chronic renal failure took part in a controlled study of the effects of 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> and D<jats:sub>3<\/jats:sub>. After a 6\u2010month observation period the patients were allocated at random to two groups for 6 months of treatment with either 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> (mean dose 0\u00b75 \u03bcg daily) or D<jats:sub>3<\/jats:sub> (dose 100 \u03bcg daily). The treatment was then discontinued and the patients were studied for a further 3 months.<\/jats:p><jats:p>In the 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> group the mean serum concentration of 1,25(OH)<jats:sub>2<\/jats:sub>D rose significantly during treatment, whereas serum concentrations of 25OHD and 24,25(OH)<jats:sub>2<\/jats:sub>D remained unchanged. In the D<jats:sub>3<\/jats:sub> group there was a highly significant increase in serum concentrations of 25OHD and 24,25(OH)<jats:sub>2<\/jats:sub>D, whereas serum 1,25(OH)<jats:sub>2<\/jats:sub>D remained unchanged.<\/jats:p><jats:p>There was a significant fall in serum iPTH in both treatment groups. This fall was unrelated to serum calcium in the D<jats:sub>3<\/jats:sub> group unlike the findings in the 1,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> group. The data support previous experimental evidence that serum iPTH can be suppressed by 24,25(OH)<jats:sub>2<\/jats:sub>D<jats:sub>3<\/jats:sub> and suggest that this analogue may be of clinical importance in the treatment of chronic renal failure without inducing hypercalcaemia.<\/jats:p>","DOI":"10.1111\/j.1365-2265.1981.tb00660.x","type":"journal-article","created":{"date-parts":[[2008,3,17]],"date-time":"2008-03-17T13:06:03Z","timestamp":1205759163000},"page":"237-242","source":"Crossref","is-referenced-by-count":7,"title":["A POSSIBLE DIRECT EFFECT OF 24,25\u2010DIHYDROXYCHOLECALCIFEROL ON THE PARATHYROID GLAND IN PATIENTS WITH CHRONIC RENAL FAILURE"],"prefix":"10.1111","volume":"15","author":[{"given":"C.","family":"CHRISTIANSEN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"R\u00f8dbro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"N\u00c6STOFT","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"MERETE S.","family":"CHRISTENSEN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,3,17]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)91137-6"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-46-2-284"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197211022871801"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109055"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109701"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365517609055266"},{"key":"e_1_2_1_8_1","first-page":"528","article-title":"Endocrine effects of lithium. II. \u2018Primary\u2019 hyperparathyroidism","volume":"88","author":"Christiansen C.","year":"1978","journal-title":"Acta Endocrinologica"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.1981.tb00659.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0022-4731(79)90275-9"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1159\/000403275"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000403272"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/0221-8747(79)90013-4"},{"key":"e_1_2_1_14_1","unstructured":"Pedersen K.O.(1973)Calcium in human serum biochemical and clinical aspects.Thesis University of Aarhus Denmark ."},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1042\/bj1820055"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.183.4130.1198"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2265.1981.tb00660.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2265.1981.tb00660.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,11]],"date-time":"2023-11-11T13:27:14Z","timestamp":1699709234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2265.1981.tb00660.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1981,9]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[1981,9]]}},"alternative-id":["10.1111\/j.1365-2265.1981.tb00660.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2265.1981.tb00660.x","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[1981,9]]}}}